Familial Chylomicronemia Syndrome | FCS Treatment Options
Familial Chylomicronemia Syndrome
About FCS
Symptoms and Diagnosis
Management of FCS


Researchers are currently working to develop a therapy with the potential to reduce levels of apoC-III in the blood. ApoC-III is a protein proven to regulate triglycerides. Therefore, reducing the amount of apoC-III may help lower elevated triglycerides, a significant risk factor for pancreatitis.

Volanersorsen is an investigational therapy designed to reduce the amount of apoC-III in the bloodstream. In a clinical trial in patients with hypertriglyceridemia, clinicians observed that subjects treated with volanesorsen had substantially reduced triglyceride levels. The results of another randomized, double-blind clinical study of 66 patients with FCS show that treatment with volanesorsen resulted in an average 77% reduction in triglyceride levels after 3 months. A reduction in triglycerides was maintained for the duration of the study (52 weeks). For more information about this study, visit http://akceatx.com/.
Content funded by Akcea Therapeutics and developed in collaboration with Rare Disease Report. All material on this website protected by copyright, Copyright 2017 Rare Disease Communications®
Terms and Conditions